IMPACT study on intervening with a manualised package to achieve treatment adherence in people with tuberculosis: protocol paper for a mixed-methods study, including a pilot randomised controlled trial

Introduction Compared with the rest of the UK and Western Europe, England has high rates of the infectious disease tuberculosis (TB). TB is curable, although treatment is for at least 6 months and longer when disease is drug resistant. If patients miss too many doses (non-adherence), they may transmit infection for longer and the infecting bacteria may develop resistance to the standard drugs used for treatment. Non-adherence may therefore risk both their health and that of others. Within England, certain population groups are thought to be at higher risk of non-adherence, but the factors contributing to this have been insufficiently determined, as have the best interventions to promote adherence. The objective of this study was to develop a manualised package of interventions for use as part of routine care within National Health Services to address the social and cultural factors that lead to poor adherence to treatment for TB disease. Methods and analysis This study uses a mixed-methods approach, with six study components. These are (1) scoping reviews of the literature; (2) qualitative research with patients, carers and healthcare professionals; (3) development of the intervention; (4) a pilot randomised controlled trial of the manualised intervention; (5) a process evaluation to examine clinical utility; and (6) a cost analysis. Ethics and dissemination This study received ethics approval on 24 December 2018 from Camberwell St. Giles Ethics Committee, UK (REC reference 18/LO/1818). Findings will be published and disseminated through peer-reviewed publications and conference presentations, published in an end of study report to our funder (the National Institute for Health Research, UK) and presented to key stakeholders. Trial registration number ISRCTN95243114 Secondary identifying numbers University College London/University College London Hospitals Joint Research Office 17/0726. National Institute for Health Research, UK 16/88/06.

[1]  John L. Johnson,et al.  A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis , 2018, Nature Medicine.

[2]  H. Dongmei,et al.  Evaluation of a medication monitor-based treatment strategy for drug-sensitive tuberculosis patients in China: study protocol for a cluster randomised controlled trial , 2018, Trials.

[3]  Z. Mor,et al.  Risk Factors for Recurrent Tuberculosis among Successfully Treated Patients in Israel, 1999-2011. , 2017, The Israel Medical Association journal : IMAJ.

[4]  G. Cooke,et al.  Drug resistant TB: UK multicentre study (DRUMS): Treatment, management and outcomes in London and West Midlands 2008-2014. , 2017, The Journal of infection.

[5]  V. Sequera,et al.  How do we measure adherence to anti-tuberculosis treatment? , 2017, Expert review of anti-infective therapy.

[6]  Sebastian Bonhoeffer,et al.  The Role of Adherence and Retreatment in De Novo Emergence of MDR-TB , 2016, PLoS Comput. Biol..

[7]  M. Bonnet,et al.  Effects of treatment interruption patterns on treatment success among patients with multidrug-resistant tuberculosis in Armenia and Abkhazia. , 2015, The Journal of infectious diseases.

[8]  N. Gale,et al.  Using the framework method for the analysis of qualitative data in multi-disciplinary health research , 2013, BMC Medical Research Methodology.

[9]  F. Cobelens,et al.  Adherence to Tuberculosis Treatment, Sputum Smear Conversion and Mortality: A Retrospective Cohort Study in 48 Rwandan Clinics , 2013, PloS one.

[10]  M. T. Gler,et al.  Patterns of Treatment Interruption among Patients with Multidrug-Resistant TB (MDR TB) and Association with Interim and Final Treatment Outcomes , 2013, PloS one.

[11]  P. Nyasulu,et al.  Levels of Tuberculosis Treatment Adherence among Sputum Smear Positive Pulmonary Tuberculosis Patients Attending Care at Zomba Central Hospital, Southern Malawi, 2007–2008 , 2013, PloS one.

[12]  Jeffrey K Aronson,et al.  A new taxonomy for describing and defining adherence to medications. , 2012, British journal of clinical pharmacology.

[13]  G. Kibiki,et al.  The complexity of the adherence‐response relationship in tuberculosis treatment: why are we still in the dark and how can we get out? , 2011, Tropical medicine & international health : TM & IH.

[14]  S. Michie,et al.  The behaviour change wheel: A new method for characterising and designing behaviour change interventions , 2011, Implementation science : IS.

[15]  G. Bonsel,et al.  Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) , 2011, Quality of Life Research.

[16]  M. Blaxter,et al.  Deep resequencing of serial sputum isolates of Mycobacterium tuberculosis during therapeutic failure due to poor compliance reveals stepwise mutation of key resistance genes on an otherwise stable genetic background. , 2011, The Journal of infection.

[17]  Sonya S. Shin,et al.  Development of extensively drug-resistant tuberculosis during multidrug-resistant tuberculosis treatment. , 2010, American journal of respiratory and critical care medicine.

[18]  Elizabeth Broadbent,et al.  The brief illness perception questionnaire. , 2006, Journal of psychosomatic research.

[19]  B. Löwe,et al.  A brief measure for assessing generalized anxiety disorder: the GAD-7. , 2006, Archives of internal medicine.

[20]  Chandrasekaran,et al.  Predictors of relapse among pulmonary tuberculosis patients treated in a DOTS programme in South India. , 2005, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[21]  S. De Geest,et al.  Adherence to Long-Term Therapies: Evidence for Action , 2003, European journal of cardiovascular nursing : journal of the Working Group on Cardiovascular Nursing of the European Society of Cardiology.

[22]  A. Hayward,et al.  Risk factors for drug resistant tuberculosis in Leicestershire – poor adherence to treatment remains an important cause of resistance , 2003, Epidemiology and Infection.

[23]  R. Spitzer,et al.  The PHQ-9 , 2001, Journal of General Internal Medicine.

[24]  Jeffrey N. Martin,et al.  The changing epidemiology of acquired drug-resistant tuberculosis in San Francisco, USA , 1996, The Lancet.

[25]  R. J. Hayes,et al.  Cluster randomised trials, second edition , 2017 .

[26]  B. Giraudeau,et al.  [Cluster randomised trials]. , 2014, Annales de dermatologie et de venereologie.

[27]  Nick Barber,et al.  Concordance , adherence and compliance in medicine taking Report for the National Co-ordinating Centre for NHS Service Delivery and Organisation , 2010 .

[28]  Nick Barber,et al.  Concordabe, adherence and Compliance in Medicine Taking , 2005 .

[29]  J. Weinman,et al.  The beliefs about medicines questionnaire: The development and evaluation of a new method for assessing the cognitive representation of medication , 1999 .